BACKGROUND
MEK inhibition has demonstrated activity in pediatric low-grade gliomas (pLGGs) driven by BRAF rearrangements, but data on trametinib remain limited, regarding efficacy, short and long-term toxicities.
METHODS
We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs rec...
Céline Khouri, Amandine Bibollet, Y. Bouchoucha et al.· European Journal of Cancer· 0 citations
INTRODUCTION
The 2021 World Health Organisation (WHO) classification of the Central Nervous System tumors introduced, for the first time, a molecular biomarker (homozygous deletion of CDKN2A/B) into the grading of astrocytomas, IDH-mutant. Since then, the cIMPACT-NOW expert group has proposed a new prognostic algorithm...
A. Tauziède-Espariat, Alice Métais, F. Sassi et al.· Annales de Pathologie· 0 citations
PURPOSE
Rhabdoid tumors (RTs) are highly aggressive pediatric cancers driven by the biallelic inactivation of the SMARCB1 tumor suppressor gene, the sole recurrent genetic alteration. SMARCB1 encodes a core subunit of the SWI/SNF chromatin remodeling complex; its loss disrupts epigenetic gene regulation, supporting the...
C. Chauvin, Ryszard Wimmer, Ludovica Brunetti et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.